130 related articles for article (PubMed ID: 12714496)
1. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells.
Selleri C; Maciejewski JP; Montuori N; Ricci P; Visconte V; Serio B; Luciano L; Rotoli B
Blood; 2003 Aug; 102(4):1490-8. PubMed ID: 12714496
[TBL] [Abstract][Full Text] [Related]
2. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
Pan J; She M; Xu ZX; Sun L; Yeung SC
Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
[TBL] [Abstract][Full Text] [Related]
4. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
Pellicano F; Copland M; Jorgensen HG; Mountford J; Leber B; Holyoake TL
Blood; 2009 Nov; 114(19):4186-96. PubMed ID: 19738029
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells.
Suzuki N; Urano J; Tamanoi F
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15356-61. PubMed ID: 9860973
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
[TBL] [Abstract][Full Text] [Related]
8. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
9.
Giudice V; Ricci P; Marino L; Rocco M; Villani G; Langella M; Manente L; Seneca E; Ferrara I; Pezzullo L; Serio B; Selleri C
Transl Med UniSa; 2016 Nov; 15():22-33. PubMed ID: 27896224
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
16. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.
Pellicano F; Simara P; Sinclair A; Helgason GV; Copland M; Grant S; Holyoake TL
Leukemia; 2011 Jul; 25(7):1159-67. PubMed ID: 21483442
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
19. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.
Jiang K; Coppola D; Crespo NC; Nicosia SV; Hamilton AD; Sebti SM; Cheng JQ
Mol Cell Biol; 2000 Jan; 20(1):139-48. PubMed ID: 10594016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
